Compare LZM & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LZM | AQST |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | Isle of Man | United States |
| Employees | 93 | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 460.6M | 504.0M |
| IPO Year | N/A | 2007 |
| Metric | LZM | AQST |
|---|---|---|
| Price | $4.62 | $4.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $7.00 | ★ $9.00 |
| AVG Volume (30 Days) | 874.0K | ★ 1.6M |
| Earning Date | 03-19-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | $86.37 | $10.08 |
| Revenue Next Year | $202.49 | $49.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $3.06 | $2.22 |
| 52 Week High | $6.40 | $7.55 |
| Indicator | LZM | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 42.63 | 48.04 |
| Support Level | $3.83 | $3.70 |
| Resistance Level | $4.80 | $4.38 |
| Average True Range (ATR) | 0.43 | 0.21 |
| MACD | -0.13 | 0.00 |
| Stochastic Oscillator | 2.22 | 16.35 |
Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania, and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate. Geographically, the company operates in South Africa, Australia, and the rest of the world. The majority of its revenue is generated from Australia.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.